KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Return on Sales (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Return on Sales data on record, last reported at 47.52% in Q4 2025.

  • For Q4 2025, Return on Sales rose 4799.0% year-over-year to 47.52%; the TTM value through Dec 2025 reached 0.68%, up 27.0%, while the annual FY2025 figure was 22.09%, 2274.0% up from the prior year.
  • Return on Sales reached 47.52% in Q4 2025 per IONS's latest filing, up from 0.82% in the prior quarter.
  • Across five years, Return on Sales topped out at 47.52% in Q4 2025 and bottomed at 2208.83% in Q2 2024.
  • Average Return on Sales over 5 years is 109.33%, with a median of 0.71% recorded in 2021.
  • Peak YoY movement for Return on Sales: plummeted -220838bps in 2024, then surged 220928bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 4.24% in 2021, then plummeted by -108bps to 0.35% in 2022, then soared by 390bps to 1.0% in 2023, then crashed by -146bps to 0.46% in 2024, then surged by 10354bps to 47.52% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 47.52% in Q4 2025, 0.82% in Q3 2025, and 0.44% in Q2 2025.